Karl‐Otfried Schwab

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith et al. · The Lancet Diabetes & Endocrinology · 2023 · 98 citations · Full text

Metabolic Syndrome, Diabetes Management, Young People +11

Constitutively active germline mutation of the thyrotropin receptor gene as a cause of congenital hyperthyroidism

Karl‐Otfried Schwab, M. Gerlich, M. Broecker et al. · The Journal of Pediatrics · 1997 · 50 citations

Developmental Biology, Congenital Hyperthyroidism, Genetics +9

Free epinephrine, norepinephrine and dopamine in saliva and plasma of healthy adults.

Karl‐Otfried Schwab, G Heubel, Hans‐Jochen Bartels · PubMed · 1992 · 49 citations

Psychopharmacology, Salivary Gland, Salivary Catecholamine Levels +18

Mutations of the TSH receptor as cause of congenital hyperthyroidism^*

Karl‐Otfried Schwab, P. Söhlemann, M. Gerlich et al. · Experimental and Clinical Endocrinology & Diabetes · 2009 · 36 citations

Plasma catecholamines after endotracheal administration of adrenaline during postnatal resuscitation.

Karl‐Otfried Schwab, H. B. von Stockhausen · Archives of Disease in Childhood Fetal & Neonatal · 1994 · 31 citations · Full text

Adrenal Gland, Sulphoconjugated Adrenaline, Neonatology +15